<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Contemp Clin Dent</journal-id><journal-id journal-id-type="iso-abbrev">Contemp Clin Dent</journal-id><journal-id journal-id-type="publisher-id">CCD</journal-id><journal-title-group><journal-title>Contemporary Clinical Dentistry</journal-title></journal-title-group><issn pub-type="ppub">0976-237X</issn><issn pub-type="epub">0976-2361</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29599587</article-id><article-id pub-id-type="pmc">5863413</article-id><article-id pub-id-type="publisher-id">CCD-9-65</article-id><article-id pub-id-type="doi">10.4103/ccd.ccd_751_17</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>To Evaluate the Efficacy of Topical Propolis in the Management of Symptomatic Oral Lichen Planus: A Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Joshy</surname><given-names>Athira</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Doggalli</surname><given-names>Nagabhushana</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Patil</surname><given-names>Karthikeya</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Kulkarni</surname><given-names>P. K.</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib></contrib-group><aff id="aff1"><italic>Department of Oral Medicine and Radiology, JSS Dental College and Hospital, Jagadguru Sri Shivarathreeshwara University, Mysore, Karnataka, India</italic></aff><aff id="aff2"><label>1</label><italic>Department of Pharmaceutics JSS College of Pharmacy, Mysore, Karnataka, India</italic></aff><author-notes><corresp id="cor1"><italic><bold>Address for correspondence:</bold> Dr. Nagabhushana Doggalli, Department of Oral Medicine and Radiology, JSS Dental College and Hospital, Jagadguru Sri Shivarathreeshwara University, JSS Medical Institutions Campus, Sri Shivarathreeshwara Nagar, Mysore - 570 015, Karnataka, India. E-mail: <email xlink:href="drbhushan@rediffmail.com">drbhushan@rediffmail.com</email></italic></corresp></author-notes><pub-date pub-type="ppub"><season>Jan-Mar</season><year>2018</year></pub-date><volume>9</volume><issue>1</issue><fpage>65</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright: © 2018 Contemporary Clinical Dentistry</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="3453" xml_f="3466" txt_i="11" txt_f="24">Introduction:</offsets></title><p><offsets xml_i="3477" xml_f="3798" txt_i="25" txt_f="346">Lichen planus (LP) is a chronic inflammatory, autoimmune, mucocutaneous disease of unknown etiology. The first line of treatment for oral LP (OLP) has been corticosteroids, but because of their adverse effects, alternative therapeutic approaches are being carried out, of which the recent natural alternative is propolis.</offsets></p></sec><sec id="st2"><title><offsets xml_i="3829" xml_f="3833" txt_i="348" txt_f="352">Aim:</offsets></title><p><offsets xml_i="3844" xml_f="3930" txt_i="353" txt_f="439">This study aims to evaluate the efficacy of topical propolis in the management of OLP.</offsets></p></sec><sec id="st3"><title><offsets xml_i="3961" xml_f="3983" txt_i="441" txt_f="463">Materials and Methods:</offsets></title><p><offsets xml_i="3994" xml_f="4383" txt_i="464" txt_f="853">The research group consisted of 27 patients diagnosed with symptomatic OLP, among which 15 patients were in the control group and the rest 12 were in the study group. The patients in the control group received triamcinolone acetonide 0.1% (topical application) while the patients in the study group received propolis gel. Both the groups were evaluated for pain and erythema at baseline (1</offsets><sup><offsets xml_i="4388" xml_f="4390" txt_i="853" txt_f="855">st</offsets></sup><offsets xml_i="4396" xml_f="4423" txt_i="855" txt_f="882"> visit), first follow-up (7</offsets><sup><offsets xml_i="4428" xml_f="4430" txt_i="882" txt_f="884">th</offsets></sup><offsets xml_i="4436" xml_f="4467" txt_i="884" txt_f="915"> day), and second follow-up (14</offsets><sup><offsets xml_i="4472" xml_f="4474" txt_i="915" txt_f="917">th</offsets></sup><offsets xml_i="4480" xml_f="4549" txt_i="917" txt_f="986"> day) using numerical rating scale and modified oral mucositis index.</offsets></p></sec><sec id="st4"><title><offsets xml_i="4580" xml_f="4588" txt_i="988" txt_f="996">Results:</offsets></title><p><offsets xml_i="4599" xml_f="4695" txt_i="997" txt_f="1093">The patients in both the study and control groups showed a statistically significant reduction (</offsets><italic><offsets xml_i="4703" xml_f="4704" txt_i="1093" txt_f="1094">P</offsets></italic><offsets xml_i="4713" xml_f="4746" txt_i="1094" txt_f="1127"> = 0.000 for the study group and </offsets><italic><offsets xml_i="4754" xml_f="4755" txt_i="1127" txt_f="1128">P</offsets></italic><offsets xml_i="4764" xml_f="5017" txt_i="1128" txt_f="1381"> = 0.000 for the control group) in pain and erythema scores from baseline to second follow-up visit. However, on comparison of the reduction in pain and erythema scores between the two groups, the difference was found to be statistically insignificant (</offsets><italic><offsets xml_i="5025" xml_f="5026" txt_i="1381" txt_f="1382">P</offsets></italic><offsets xml_i="5035" xml_f="5045" txt_i="1382" txt_f="1392"> = 0.255).</offsets></p></sec><sec id="st5"><title><offsets xml_i="5076" xml_f="5102" txt_i="1394" txt_f="1420">Statistical Analysis Used:</offsets></title><p><offsets xml_i="5113" xml_f="5154" txt_i="1421" txt_f="1462">Chi-square and Cramer's V test were used.</offsets></p></sec><sec id="st6"><title><offsets xml_i="5185" xml_f="5196" txt_i="1464" txt_f="1475">Conclusion:</offsets></title><p><offsets xml_i="5207" xml_f="5343" txt_i="1476" txt_f="1612">The topical propolis was found to be of comparative effectiveness with respect to triamcinolone acetonide 0.1% in the management of OLP.</offsets></p></sec></abstract><kwd-group><kwd><italic>Corticosteroids</italic></kwd><kwd><italic>oral lichen planus</italic></kwd><kwd><italic>propolis</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="5582" xml_f="5594" txt_i="1621" txt_f="1633">Introduction</offsets></title><p><offsets xml_i="5605" xml_f="5911" txt_i="1634" txt_f="1940">The mouth is a mirror of health or disease, a guardian, or early warning system. The oral cavity is considered as a window to the body because oral manifestations accompany many systemic diseases. In many instances, oral involvement presages the appearance of other symptoms or lesions at other locations.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="5944" xml_f="5945" txt_i="1940" txt_f="1941">1</offsets></xref><offsets xml_i="5952" xml_f="5953" txt_i="1941" txt_f="1942">]</offsets></p><p><offsets xml_i="5960" xml_f="6356" txt_i="1943" txt_f="2339">Oral lichen planus (OLP) is a chronic inflammatory, autoimmune, mucocutaneous disease of unknown etiology. The strange name of the condition was provided by the British physician Erasmus Wilson, who first described it in 1869. He named it so as the lesions on the skin looked similar to the tree mosses growing on the rocks. In Greek, “lichen” means tree moss, and in Latin, “planus” means flat.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="6389" xml_f="6390" txt_i="2339" txt_f="2340">2</offsets></xref><offsets xml_i="6397" xml_f="6398" txt_i="2340" txt_f="2341">]</offsets></p><p><offsets xml_i="6405" xml_f="6640" txt_i="2342" txt_f="2577">As the exact causative factor for OLP is a matter of conflict, the failure to achieve appropriate or exact treatment for it may be the reason for its incomplete regression. The first line of treatment for OLP has been corticosteroids,[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6673" xml_f="6674" txt_i="2577" txt_f="2578">3</offsets></xref><offsets xml_i="6681" xml_f="6778" txt_i="2578" txt_f="2675">] but because of their adverse effects, alternative therapeutic approaches are being carried out.</offsets></p><p><offsets xml_i="6785" xml_f="7021" txt_i="2676" txt_f="2912">Recently, use of natural drugs, such as propolis, has gained considerable interest. It is a sticky, resinous substance which is collected by the honey bees from the sap, leaves, and buds of plants, and then mixed with secreted beeswax.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="7054" xml_f="7055" txt_i="2912" txt_f="2913">4</offsets></xref><offsets xml_i="7062" xml_f="7162" txt_i="2913" txt_f="3013">] It has been used in folk medicine for thousands of years and is also known as Russian penicillin.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="7195" xml_f="7196" txt_i="3013" txt_f="3014">5</offsets></xref><offsets xml_i="7203" xml_f="7204" txt_i="3014" txt_f="3015">]</offsets></p><p><offsets xml_i="7211" xml_f="7372" txt_i="3016" txt_f="3177">Propolis being extremely high in bioflavonoid content has antioxidant, antibacterial, antifungal, antiviral, immunomodulatory, and anti-inflammatory properties.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="7405" xml_f="7406" txt_i="3177" txt_f="3178">4</offsets></xref><offsets xml_i="7413" xml_f="7646" txt_i="3178" txt_f="3411">] These properties have prompted investigators to check its efficacy on various oral diseases, namely lichen planus (LP), oral candidiasis, recurrent aphthous stomatitis, radiation mucositis, denture stomatitis, and herpes labialis.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="7679" xml_f="7680" txt_i="3411" txt_f="3412">6</offsets></xref><offsets xml_i="7687" xml_f="7688" txt_i="3412" txt_f="3413">]</offsets></p><p><offsets xml_i="7695" xml_f="7804" txt_i="3414" txt_f="3523">A study conducted in the past has obtained favorable results in the management of OLP using topical propolis.</offsets></p><p><offsets xml_i="7811" xml_f="7993" txt_i="3524" txt_f="3706">With this background in mind, this study was designed to evaluate the efficacy of topical propolis in the management of OLP and to further strengthen the previously obtained results.</offsets></p></sec><sec sec-type="materials|methods" id="sec1-2"><title><offsets xml_i="8056" xml_f="8077" txt_i="3708" txt_f="3729">Materials and Methods</offsets></title><sec id="sec2-1"><title><offsets xml_i="8109" xml_f="8123" txt_i="3730" txt_f="3744">Source of data</offsets></title><p><offsets xml_i="8134" xml_f="8330" txt_i="3745" txt_f="3941">The study participants comprised of dental outpatients visiting the Department of Oral Medicine and Radiology, JSS Dental College and Hospital, Jagadguru Sri Shivarathreeshwara University, Mysore.</offsets></p></sec><sec id="sec2-2"><title><offsets xml_i="8364" xml_f="8392" txt_i="3943" txt_f="3971">Method of collection of data</offsets></title><p><offsets xml_i="8403" xml_f="8626" txt_i="3972" txt_f="4195">The study sample was collected through purposive sampling. Twenty-seven individuals of either gender, satisfying the following eligibility criteria, and those willing to participate in the study were selected for the study.</offsets></p></sec><sec id="sec2-3"><title><offsets xml_i="8660" xml_f="8678" txt_i="4197" txt_f="4215">Inclusion criteria</offsets></title><p><offsets xml_i="8689" xml_f="8690" txt_i="4216" txt_f="4217">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="8729" xml_f="8832" txt_i="4217" txt_f="4320">Patients with clinically diagnosed atrophic/erosive OLP(based on modified WHO clinical criteria, 2003)[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="8865" xml_f="8866" txt_i="4320" txt_f="4321">7</offsets></xref><offsets xml_i="8873" xml_f="8874" txt_i="4321" txt_f="4322">]</offsets></p></list-item><list-item><p><offsets xml_i="8904" xml_f="9064" txt_i="4323" txt_f="4483">Individuals willing to be a part of the study, who sign the informed consent form, and who find it convenient to appear for follow-ups as required by the study.</offsets></p></list-item><list-item><p><offsets xml_i="9094" xml_f="9186" txt_i="4484" txt_f="4576">Patients who had not used systemic or topical glucocorticosteroids for at least past 2 weeks</offsets></p></list-item><list-item><p><offsets xml_i="9216" xml_f="9359" txt_i="4577" txt_f="4720">Patients who agree not to use any other medication such as analgesics and anesthetics in either topical form or systemic form during the study.</offsets></p></list-item></list><offsets xml_i="9382" xml_f="9383" txt_i="4721" txt_f="4722">
</offsets></p></sec><sec id="sec2-4"><title><offsets xml_i="9417" xml_f="9435" txt_i="4724" txt_f="4742">Exclusion criteria</offsets></title><p><offsets xml_i="9446" xml_f="9447" txt_i="4743" txt_f="4744">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="9486" xml_f="9532" txt_i="4744" txt_f="4790">Patients not willing to be a part of the study</offsets></p></list-item><list-item><p><offsets xml_i="9562" xml_f="9671" txt_i="4791" txt_f="4900">Patients with lichenoid lesions thought to arise as a hypersensitivity reaction to drugs and dental materials</offsets></p></list-item><list-item><p><offsets xml_i="9701" xml_f="9750" txt_i="4901" txt_f="4950">Patients on long-term glucocorticosteroid therapy</offsets></p></list-item><list-item><p><offsets xml_i="9780" xml_f="9818" txt_i="4951" txt_f="4989">Pregnant and lactating female patients</offsets></p></list-item><list-item><p><offsets xml_i="9848" xml_f="9882" txt_i="4990" txt_f="5024">Patients allergic to bee products.</offsets></p></list-item></list><offsets xml_i="9905" xml_f="9906" txt_i="5025" txt_f="5026">
</offsets></p><p><offsets xml_i="9913" xml_f="10353" txt_i="5027" txt_f="5467">The patients were informed about the study parameters, and signed informed consent was taken. The patients in the control group received triamcinolone acetonide 0.1% while the patients in the study group received 5% propolis. Patients in both the groups were instructed to apply the paste on the lesion three times a day for 15 days and were asked to refrain from eating, drinking, and rinsing for at least 30 min after topical application.</offsets></p><p><offsets xml_i="10360" xml_f="10522" txt_i="5468" txt_f="5630">Symptom score for OLP was considered at baseline using numerical rating scale (NRS) ranging from 0 (no oral discomfort) to 10 (worst imaginable oral discomfort) [</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="10552" xml_f="10560" txt_i="5630" txt_f="5638">Figure 1</offsets></xref><offsets xml_i="10567" xml_f="10570" txt_i="5638" txt_f="5641">].[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="10603" xml_f="10604" txt_i="5641" txt_f="5642">8</offsets></xref><offsets xml_i="10611" xml_f="10613" txt_i="5642" txt_f="5644">] </offsets></p><fig id="F1" position="float"><label><offsets xml_i="10654" xml_f="10662" txt_i="5645" txt_f="5653">Figure 1</offsets></label><caption><p><offsets xml_i="10682" xml_f="10704" txt_i="5653" txt_f="5675">Numerical rating scale</offsets></p></caption><graphic xlink:href="CCD-9-65-g001"></graphic></fig><p><offsets xml_i="10773" xml_f="11144" txt_i="5676" txt_f="6047">The clinical signs of OLP were measured at baseline using a semi-quantitative scale, modified oral mucositis index (MOMI), validated for measurement of clinical signs of OLP. An oral examination was conducted and atrophic and erosive changes were quantified based on severity and the number of sites involved. An intensity score for erythema ranging from 0 to 3 was used:</offsets></p><p><offsets xml_i="11151" xml_f="11152" txt_i="6048" txt_f="6049">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="11191" xml_f="11201" txt_i="6049" txt_f="6059">0 = normal</offsets></p></list-item><list-item><p><offsets xml_i="11231" xml_f="11248" txt_i="6060" txt_f="6077">1 = mild erythema</offsets></p></list-item><list-item><p><offsets xml_i="11278" xml_f="11299" txt_i="6078" txt_f="6099">2 = moderate erythema</offsets></p></list-item><list-item><p><offsets xml_i="11329" xml_f="11349" txt_i="6100" txt_f="6120">3 = severe erythema.</offsets></p></list-item></list><offsets xml_i="11372" xml_f="11373" txt_i="6121" txt_f="6122">
</offsets></p><p><offsets xml_i="11380" xml_f="11438" txt_i="6123" txt_f="6181">The score for ulcerations was based on area of ulceration:</offsets></p><p><offsets xml_i="11445" xml_f="11446" txt_i="6182" txt_f="6183">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="11485" xml_f="11503" txt_i="6183" txt_f="6201">0 = no ulcerations</offsets></p></list-item><list-item><p><offsets xml_i="11533" xml_f="11558" txt_i="6202" txt_f="6227">1 = between 0 and 0.25 cm</offsets><sup><offsets xml_i="11563" xml_f="11564" txt_i="6227" txt_f="6228">2</offsets></sup><offsets xml_i="11570" xml_f="11571" txt_i="6228" txt_f="6229">
</offsets></p></list-item><list-item><p><offsets xml_i="11601" xml_f="11626" txt_i="6230" txt_f="6255">2 = between 0.25 and 1 cm</offsets><sup><offsets xml_i="11631" xml_f="11632" txt_i="6255" txt_f="6256">2</offsets></sup><offsets xml_i="11638" xml_f="11639" txt_i="6256" txt_f="6257">
</offsets></p></list-item><list-item><p><offsets xml_i="11669" xml_f="11677" txt_i="6258" txt_f="6266">3= ≥1 cm</offsets><sup><offsets xml_i="11682" xml_f="11683" txt_i="6266" txt_f="6267">2</offsets></sup><offsets xml_i="11689" xml_f="11690" txt_i="6267" txt_f="6268">.</offsets></p></list-item></list><offsets xml_i="11713" xml_f="11714" txt_i="6269" txt_f="6270">
</offsets></p><p><offsets xml_i="11721" xml_f="11786" txt_i="6271" txt_f="6336">The following clinical parameters were assessed during follow-up:</offsets></p><p><offsets xml_i="11793" xml_f="11794" txt_i="6337" txt_f="6338">
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="11833" xml_f="11842" txt_i="6338" txt_f="6347">Pain: NRS</offsets></p></list-item><list-item><p><offsets xml_i="11872" xml_f="11901" txt_i="6348" txt_f="6377">Erythema and ulceration: MOMI</offsets></p></list-item><list-item><p><offsets xml_i="11931" xml_f="11944" txt_i="6378" txt_f="6391">Side effects.</offsets></p></list-item></list><offsets xml_i="11967" xml_f="11968" txt_i="6392" txt_f="6393">
</offsets></p><p><offsets xml_i="11975" xml_f="12181" txt_i="6394" txt_f="6600">The patients were followed up after 7 and 15 days. Readings for all clinical parameters for each patient from baseline to subsequent visits were recorded. The patients were inquired for side effects if any.</offsets></p><p><offsets xml_i="12188" xml_f="12395" txt_i="6601" txt_f="6808">The data were entered into the computer using Microsoft excel and were analyzed using SPSS software for windows (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp).</offsets></p><p><offsets xml_i="12402" xml_f="12521" txt_i="6809" txt_f="6928">The data were tabulated and subjected to the following statistical analysis, i.e., the Cramer's V and Chi-square test. </offsets><italic><offsets xml_i="12529" xml_f="12530" txt_i="6928" txt_f="6929">P</offsets></italic><offsets xml_i="12539" xml_f="12594" txt_i="6929" txt_f="6981"> &lt; 0.05 was considered as statistically significant.</offsets></p></sec><sec id="sec2-5"><title><offsets xml_i="12628" xml_f="12651" txt_i="6983" txt_f="7006">Preparation of propolis</offsets></title><p><offsets xml_i="12662" xml_f="12763" txt_i="7007" txt_f="7108">Preparation of propolis was done in the Department of Pharmaceutics, JSS College of Pharmacy, Mysore.</offsets></p><sec id="sec3-1"><title><offsets xml_i="12791" xml_f="12805" txt_i="7109" txt_f="7123">Chemicals used</offsets></title><p><offsets xml_i="12816" xml_f="12926" txt_i="7124" txt_f="7234">Ethanol, starch powder, carbopol 934, triethanolamine (TEA), methylparaben, propylparaben, and peppermint oil.</offsets></p></sec><sec id="sec3-2"><title><offsets xml_i="12960" xml_f="12974" txt_i="7236" txt_f="7250">Equipment used</offsets></title><p><offsets xml_i="12985" xml_f="13049" txt_i="7251" txt_f="7315">Digital weighing balance, Magnetic stirrer, and Propeller mixer.</offsets></p><p><offsets xml_i="13056" xml_f="13205" txt_i="7316" txt_f="7465">The propolis was cleaned using sterile hand gloves and was cut into small pieces, and 400 g of cleaned propolis was considered for the present study.</offsets></p><p><offsets xml_i="13212" xml_f="13453" txt_i="7466" txt_f="7707">A sterilized 1000 ml beaker was filled with about 500 ml of absolute alcohol and approximately 400 g of propolis was added. It was then covered with aluminum foil which was kept in a warm dark place for 7 days to achieve complete extraction.</offsets></p><p><offsets xml_i="13460" xml_f="13724" txt_i="7708" txt_f="7972">After 7 days, the contents in the conical flask were filtered using filter paper, and the solution was collected in a clean beaker. It was then subjected to evaporation using the magnetic stirrer to remove excess of solvent. The temperature was maintained at 40°C.</offsets></p><p><offsets xml_i="13731" xml_f="13940" txt_i="7973" txt_f="8182">The resultant thick dark brown-colored liquid of 100 ml was collected in a clean beaker, and 500 gm of starch (99% pure) was added to remove the stickiness as well as to transform the extract to a powder form.</offsets></p><p><offsets xml_i="13947" xml_f="14200" txt_i="8183" txt_f="8436">Then, 1% carbopol solution (2 g in 200 ml of water) was prepared separately in a sterilized beaker to which 0.40 g of methylparaben, 0.30 g of propylparaben, and 0.75 ml of peppermint oil were added and stirred continuously to get a homogeneous mixture.</offsets></p><p><offsets xml_i="14207" xml_f="14468" txt_i="8437" txt_f="8698">The starch-mixed propolis powder extract was then added to the beaker and homogenized using propeller mixer at 250 rpm for 15 min. After that, 1 ml of TEA (neutralizing agent/thickening agent) was added to thicken the solution into a gel of desired consistency.</offsets></p><p><offsets xml_i="14475" xml_f="14778" txt_i="8699" txt_f="9002">Finally, the preparation was packed in the preweighed sterilized aluminium tubes and sealed. It was packed in such a way that 1 aluminium tube contains 25 gm of the formulation and 1 g of the formulation consists 0.2 g of the extract. Therefore, each aluminium tube consists of 5 gm of propolis extract.</offsets></p></sec></sec></sec><sec sec-type="results" id="sec1-3"><title><offsets xml_i="14843" xml_f="14850" txt_i="9006" txt_f="9013">Results</offsets></title><p><offsets xml_i="14861" xml_f="15209" txt_i="9014" txt_f="9362">Of the 27 patients enrolled in the study, 15 were in the control group and 12 were in the study group. The patients in the control group received triamcinolone acetonide 0.1%, and the patients in the study group received propolis. They were instructed to apply the paste on the lesion three times a day for 15 days and were asked to report on the 7</offsets><sup><offsets xml_i="15214" xml_f="15216" txt_i="9362" txt_f="9364">th</offsets></sup><offsets xml_i="15222" xml_f="15233" txt_i="9364" txt_f="9375"> and the 15</offsets><sup><offsets xml_i="15238" xml_f="15240" txt_i="9375" txt_f="9377">th</offsets></sup><offsets xml_i="15246" xml_f="15307" txt_i="9377" txt_f="9438"> day. Demographics and clinical characteristics are shown in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="15339" xml_f="15346" txt_i="9438" txt_f="9445">Table 1</offsets></xref><offsets xml_i="15353" xml_f="15358" txt_i="9445" txt_f="9450"> and </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="15388" xml_f="15395" txt_i="9450" txt_f="9457">Graph 1</offsets></xref><offsets xml_i="15402" xml_f="15553" txt_i="9457" txt_f="9608">. There were no significant differences between the two groups with regard to age, sex, clinical characteristic, pain, and erythema scores at baseline.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="15601" xml_f="15608" txt_i="9609" txt_f="9616">Table 1</offsets></label><caption><p><offsets xml_i="15628" xml_f="15698" txt_i="9616" txt_f="9686">Demographic data of the study participants and patient characteristics</offsets></p></caption><graphic xlink:href="CCD-9-65-g002"></graphic></table-wrap><fig id="F2" position="float"><label><offsets xml_i="15808" xml_f="15815" txt_i="9687" txt_f="9694">Graph 1</offsets></label><caption><p><offsets xml_i="15835" xml_f="16004" txt_i="9694" txt_f="9863">Change in pain scores from baseline to first follow-up, first follow-up to second follow-up visit, and baseline to second follow-up visit in the study and control groups</offsets></p></caption><graphic xlink:href="CCD-9-65-g003"></graphic></fig><p><offsets xml_i="16073" xml_f="16236" txt_i="9864" txt_f="10027">The patients in both the groups, i.e., the study group and the control group reported a complete reduction in the intensity of pain at the second follow-up visit [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="16268" xml_f="16275" txt_i="10027" txt_f="10034">Table 2</offsets></xref><offsets xml_i="16282" xml_f="16423" txt_i="10034" txt_f="10175">]. An overall statistically significant improvement in the pain scores was found from baseline to second follow-up visit in both the groups (</offsets><italic><offsets xml_i="16431" xml_f="16432" txt_i="10175" txt_f="10176">P</offsets></italic><offsets xml_i="16441" xml_f="16521" txt_i="10176" txt_f="10256"> = 0.000), but no significant differences were observed between the two groups (</offsets><italic><offsets xml_i="16529" xml_f="16530" txt_i="10256" txt_f="10257">P</offsets></italic><offsets xml_i="16539" xml_f="16549" txt_i="10257" txt_f="10267"> = 0.255).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="16597" xml_f="16604" txt_i="10268" txt_f="10275">Table 2</offsets></label><caption><p><offsets xml_i="16624" xml_f="16781" txt_i="10275" txt_f="10432">Comparison of distribution of individuals according to the improvement in pain scores from baseline to second follow-up visit in the study and control groups</offsets></p></caption><graphic xlink:href="CCD-9-65-g004"></graphic></table-wrap><p><offsets xml_i="16857" xml_f="16968" txt_i="10433" txt_f="10544">In the control group, all the patients reported complete resolution of erythema at the second follow-up visit [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="17000" xml_f="17007" txt_i="10544" txt_f="10551">Table 3</offsets></xref><offsets xml_i="17014" xml_f="17019" txt_i="10551" txt_f="10556"> and </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="17049" xml_f="17056" txt_i="10556" txt_f="10563">Graph 2</offsets></xref><offsets xml_i="17063" xml_f="17219" txt_i="10563" txt_f="10719">]. An overall statistically significant improvement was found in the erythema scores in the control group patients from baseline to second follow-up visit (</offsets><italic><offsets xml_i="17227" xml_f="17228" txt_i="10719" txt_f="10720">P</offsets></italic><offsets xml_i="17237" xml_f="17247" txt_i="10720" txt_f="10730"> = 0.000).</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="17295" xml_f="17302" txt_i="10731" txt_f="10738">Table 3</offsets></label><caption><p><offsets xml_i="17322" xml_f="17483" txt_i="10738" txt_f="10899">Comparison of distribution of individuals according to the improvement in erythema scores from baseline to second follow-up visit in the study and control groups</offsets></p></caption><graphic xlink:href="CCD-9-65-g005"></graphic></table-wrap><fig id="F3" position="float"><label><offsets xml_i="17593" xml_f="17600" txt_i="10900" txt_f="10907">Graph 2</offsets></label><caption><p><offsets xml_i="17620" xml_f="17793" txt_i="10907" txt_f="11080">Change in erythema scores from baseline to first follow-up, first follow-up to second follow-up visit, and baseline to second follow-up visit in the study and control groups</offsets></p></caption><graphic xlink:href="CCD-9-65-g006"></graphic></fig><p><offsets xml_i="17862" xml_f="18094" txt_i="11081" txt_f="11313">Among 12 patients in the study group, 11 patients reported complete resolution of erythema and 1 patient had a score of 1 (mild erythema). There was an overall improvement in the erythema scores which was statistically significant [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="18126" xml_f="18133" txt_i="11313" txt_f="11320">Table 2</offsets></xref><offsets xml_i="18140" xml_f="18217" txt_i="11320" txt_f="11397">]. However, no significant differences were observed between the two groups (</offsets><italic><offsets xml_i="18225" xml_f="18226" txt_i="11397" txt_f="11398">P</offsets></italic><offsets xml_i="18235" xml_f="18245" txt_i="11398" txt_f="11408"> = 0.255).</offsets></p><p><offsets xml_i="18252" xml_f="18342" txt_i="11409" txt_f="11499">The patients in the study and control group showed a statistically significant reduction (</offsets><italic><offsets xml_i="18350" xml_f="18351" txt_i="11499" txt_f="11500">P</offsets></italic><offsets xml_i="18360" xml_f="18393" txt_i="11500" txt_f="11533"> = 0.000 for the study group and </offsets><italic><offsets xml_i="18401" xml_f="18402" txt_i="11533" txt_f="11534">P</offsets></italic><offsets xml_i="18411" xml_f="18668" txt_i="11534" txt_f="11791"> = 0.000 for the control group) in the pain and erythema scores from baseline to second follow-up visit. However, on comparison of the reduction in pain and erythema scores between the two groups, the difference was found to be statistically insignificant (</offsets><italic><offsets xml_i="18676" xml_f="18677" txt_i="11791" txt_f="11792">P</offsets></italic><offsets xml_i="18686" xml_f="18703" txt_i="11792" txt_f="11809"> = 0.255) [Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="18735" xml_f="18737" txt_i="11809" txt_f="11811">4a</offsets></xref><offsets xml_i="18744" xml_f="18749" txt_i="11811" txt_f="11816"> and </offsets><xref ref-type="table" rid="T4"><offsets xml_i="18781" xml_f="18782" txt_i="11816" txt_f="11817">b</offsets></xref><offsets xml_i="18789" xml_f="18946" txt_i="11817" txt_f="11974">]. In other words, an intragroup analysis showed significant differences in each group, but the intergroup analysis did not show any significant differences.</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="18994" xml_f="19002" txt_i="11975" txt_f="11983">Table 4a</offsets></label><caption><p><offsets xml_i="19022" xml_f="19131" txt_i="11983" txt_f="12092">Comparison of baseline, first, and second follow-up values for various parameters of study and control groups</offsets></p></caption><graphic xlink:href="CCD-9-65-g007"></graphic></table-wrap><table-wrap id="T5" position="float"><label><offsets xml_i="19248" xml_f="19256" txt_i="12093" txt_f="12101">Table 4b</offsets></label><caption><p><offsets xml_i="19276" xml_f="19385" txt_i="12101" txt_f="12210">Comparison of baseline, first, and second follow-up values for various parameters of study and control groups</offsets></p></caption><graphic xlink:href="CCD-9-65-g008"></graphic></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="19510" xml_f="19520" txt_i="12212" txt_f="12222">Discussion</offsets></title><p><offsets xml_i="19531" xml_f="19947" txt_i="12223" txt_f="12639">LP is a chronic inflammatory, autoimmune, mucocutaneous disease of unknown etiology. As the exact causative factor for OLP is a matter of conflict, the failure to achieve appropriate or exact treatment for it may be the reason for its incomplete regression. The first line of treatment for OLP has been corticosteroids, but because of their adverse effects, alternative therapeutic approaches are being carried out.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="19980" xml_f="19981" txt_i="12639" txt_f="12640">3</offsets></xref><offsets xml_i="19988" xml_f="19989" txt_i="12640" txt_f="12641">]</offsets></p><p><offsets xml_i="19996" xml_f="20466" txt_i="12642" txt_f="13112">Recently, use of natural drugs, such as propolis, has gained considerable interest. It is a sticky, resinous substance which is collected by the honey bees from the sap, leaves, and buds of plants, and then mixed with secreted beeswax. It has been used extensively in ayurvedic medicine for centuries, as it has a diversity of therapeutic properties including antioxidant, anti-inflammatory, antibacterial, antiviral, antifungal, antitumor, and immunomodulatory effect.[</offsets><xref rid="ref4" ref-type="bibr"><offsets xml_i="20499" xml_f="20500" txt_i="13112" txt_f="13113">4</offsets></xref><offsets xml_i="20507" xml_f="20724" txt_i="13113" txt_f="13330">] These properties have prompted investigators to check its efficacy on various oral diseases, namely LP, oral candidiasis, recurrent aphthous stomatitis, radiation mucositis, denture stomatitis, and herpes labialis.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="20757" xml_f="20758" txt_i="13330" txt_f="13331">9</offsets></xref><offsets xml_i="20765" xml_f="20766" txt_i="13331" txt_f="13332">]</offsets></p><p><offsets xml_i="20773" xml_f="21743" txt_i="13333" txt_f="14303">The role of the immune system as a primary factor in the pathogenesis of LP has become established in recent years. It is attributed to the basal layer degeneration and band-like infiltration of T lymphocytes and macrophages. T helper 1 and T helper 2 are the well-known independent subdivisions of T cells. Recently, a third “T helper” subdivision has been recognized, which plays a principal role in defense against extracellular pathogens. This subdivision of T cells controls immune and inflammatory responses through secretion of cytokines such as Interleukin 17. This family of T cells provides a new route for cooperation between innate and acquired immunity. The major role of IL-17 is to increase the expression of threatening factors for colony chemokines, metalloproteinase, and IL-6. Therefore, IL-17 is a strong stimulator for recalling, activating, and immigration of neutrophils, production of INF-alpha, IL-B from macrophages, and recalling eosinophils.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="21777" xml_f="21779" txt_i="14303" txt_f="14305">10</offsets></xref><offsets xml_i="21786" xml_f="21787" txt_i="14305" txt_f="14306">]</offsets></p><p><offsets xml_i="21794" xml_f="21815" txt_i="14307" txt_f="14328">In a study by Zenouz </offsets><italic><offsets xml_i="21823" xml_f="21828" txt_i="14328" txt_f="14333">et al</offsets></italic><offsets xml_i="21837" xml_f="22001" txt_i="14333" txt_f="14497">., it was proven that propolis administration significantly decreased IL-17 serum levels, VAS means, and the maximum lesion sizes in patients with symptomatic OLP.[</offsets><xref rid="ref11" ref-type="bibr"><offsets xml_i="22035" xml_f="22037" txt_i="14497" txt_f="14499">11</offsets></xref><offsets xml_i="22044" xml_f="22045" txt_i="14499" txt_f="14500">]</offsets></p><p><offsets xml_i="22052" xml_f="22079" txt_i="14501" txt_f="14528">A study conducted by Zyada </offsets><italic><offsets xml_i="22087" xml_f="22092" txt_i="14528" txt_f="14533">et al</offsets></italic><offsets xml_i="22101" xml_f="22184" txt_i="14533" txt_f="14616">. also obtained favorable results in the management of OLP using topical propolis.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="22218" xml_f="22220" txt_i="14616" txt_f="14618">12</offsets></xref><offsets xml_i="22227" xml_f="22228" txt_i="14618" txt_f="14619">]</offsets></p><p><offsets xml_i="22235" xml_f="22437" txt_i="14620" txt_f="14822">Hence, we hypothesized that propolis could minimize the underlying inflammatory mechanism by lowering the levels of IL-17, thereby preventing the destruction of the basement membrane by the lymphocytes.</offsets></p><p><offsets xml_i="22444" xml_f="22626" txt_i="14823" txt_f="15005">With this background in mind, this study was designed to evaluate the efficacy of topical propolis in the management of OLP and to further strengthen the previously obtained results.</offsets></p><p><offsets xml_i="22633" xml_f="22920" txt_i="15006" txt_f="15293">The demographic pattern and clinical profile of OLP patients were also recorded in our study. According to our study, the patients were in the age group of 28–60 years and their mean age was 45.3 years which was almost similar to the study conducted by Tak, Gumru, Mostafa, and Chitturi.</offsets></p><p><offsets xml_i="22927" xml_f="22959" txt_i="15294" txt_f="15326">The study conducted by Chitturi </offsets><italic><offsets xml_i="22967" xml_f="22972" txt_i="15326" txt_f="15331">et al</offsets></italic><offsets xml_i="22981" xml_f="23078" txt_i="15331" txt_f="15428">. comprised of 58 patients from the age group of 11–70 years and their mean age was 45.72 years.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="23112" xml_f="23114" txt_i="15428" txt_f="15430">13</offsets></xref><offsets xml_i="23121" xml_f="23122" txt_i="15430" txt_f="15431">]</offsets></p><p><offsets xml_i="23129" xml_f="23291" txt_i="15432" txt_f="15594">According to the study conducted by Mostafa and Ahmed, Tak and Chalkoo, and Gümrü, the mean age was found to be 48 years, 43 years, and 49.8 years, respectively.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="23325" xml_f="23327" txt_i="15594" txt_f="15596">14</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="23368" xml_f="23370" txt_i="15596" txt_f="15598">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="23411" xml_f="23413" txt_i="15598" txt_f="15600">16</offsets></xref><offsets xml_i="23420" xml_f="23421" txt_i="15600" txt_f="15601">]</offsets></p><p><offsets xml_i="23428" xml_f="23531" txt_i="15602" txt_f="15705">In the present study, the mean age was 45.3 years which was more than the mean age reported by Keshari </offsets><italic><offsets xml_i="23539" xml_f="23544" txt_i="15705" txt_f="15710">et al</offsets></italic><offsets xml_i="23553" xml_f="23565" txt_i="15710" txt_f="15722">. and Munde </offsets><italic><offsets xml_i="23573" xml_f="23578" txt_i="15722" txt_f="15727">et al</offsets></italic><offsets xml_i="23587" xml_f="23637" txt_i="15727" txt_f="15777">. and lower than the mean age reported by Ingafou </offsets><italic><offsets xml_i="23645" xml_f="23650" txt_i="15777" txt_f="15782">et al</offsets></italic><offsets xml_i="23659" xml_f="23671" txt_i="15782" txt_f="15794">., Gandolfo </offsets><italic><offsets xml_i="23679" xml_f="23684" txt_i="15794" txt_f="15799">et al</offsets></italic><offsets xml_i="23693" xml_f="23704" txt_i="15799" txt_f="15810">., and Xue </offsets><italic><offsets xml_i="23712" xml_f="23717" txt_i="15810" txt_f="15815">et al</offsets></italic><offsets xml_i="23726" xml_f="23813" txt_i="15815" txt_f="15902">. This variation might be due to the difference in ethnicity and geographic locations.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="23847" xml_f="23849" txt_i="15902" txt_f="15904">17</offsets></xref><xref rid="ref18" ref-type="bibr"><offsets xml_i="23890" xml_f="23892" txt_i="15904" txt_f="15906">18</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="23933" xml_f="23935" txt_i="15906" txt_f="15908">19</offsets></xref><xref rid="ref20" ref-type="bibr"><offsets xml_i="23976" xml_f="23978" txt_i="15908" txt_f="15910">20</offsets></xref><xref rid="ref21" ref-type="bibr"><offsets xml_i="24019" xml_f="24021" txt_i="15910" txt_f="15912">21</offsets></xref><offsets xml_i="24028" xml_f="24029" txt_i="15912" txt_f="15913">]</offsets></p><p><offsets xml_i="24036" xml_f="24075" txt_i="15914" txt_f="15953">The mean age group reported by Keshari </offsets><italic><offsets xml_i="24083" xml_f="24088" txt_i="15953" txt_f="15958">et al</offsets></italic><offsets xml_i="24097" xml_f="24106" txt_i="15958" txt_f="15967">., Munde </offsets><italic><offsets xml_i="24114" xml_f="24119" txt_i="15967" txt_f="15972">et al</offsets></italic><offsets xml_i="24128" xml_f="24139" txt_i="15972" txt_f="15983">., Ingafou </offsets><italic><offsets xml_i="24147" xml_f="24152" txt_i="15983" txt_f="15988">et al</offsets></italic><offsets xml_i="24161" xml_f="24173" txt_i="15988" txt_f="16000">., Gandolfo </offsets><italic><offsets xml_i="24181" xml_f="24186" txt_i="16000" txt_f="16005">et al</offsets></italic><offsets xml_i="24195" xml_f="24206" txt_i="16005" txt_f="16016">., and Xue </offsets><italic><offsets xml_i="24214" xml_f="24219" txt_i="16016" txt_f="16021">et al</offsets></italic><offsets xml_i="24228" xml_f="24309" txt_i="16021" txt_f="16102">. was 39.9 years, 36.9 years, 50.4 years, 52 years, and 56.7 years, respectively.</offsets></p><p><offsets xml_i="24316" xml_f="24449" txt_i="16103" txt_f="16236">According to our study, no sex predilection (male: female – 1.08:1) was noted which was similar to the studies conducted by Chitturi </offsets><italic><offsets xml_i="24457" xml_f="24462" txt_i="16236" txt_f="16241">et al</offsets></italic><offsets xml_i="24471" xml_f="24482" txt_i="16241" txt_f="16252">., Ingafou </offsets><italic><offsets xml_i="24490" xml_f="24495" txt_i="16252" txt_f="16257">et al</offsets></italic><offsets xml_i="24504" xml_f="24512" txt_i="16257" txt_f="16265">., Lacy </offsets><italic><offsets xml_i="24520" xml_f="24525" txt_i="16265" txt_f="16270">et al</offsets></italic><offsets xml_i="24534" xml_f="24547" txt_i="16270" txt_f="16283">., and Anjum </offsets><italic><offsets xml_i="24555" xml_f="24560" txt_i="16283" txt_f="16288">et al</offsets></italic><offsets xml_i="24569" xml_f="24623" txt_i="16288" txt_f="16342">. where the male to female ratio was found to be 1:1.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="24657" xml_f="24659" txt_i="16342" txt_f="16344">21</offsets></xref><xref rid="ref22" ref-type="bibr"><offsets xml_i="24700" xml_f="24702" txt_i="16344" txt_f="16346">22</offsets></xref><offsets xml_i="24709" xml_f="24710" txt_i="16346" txt_f="16347">]</offsets></p><p><offsets xml_i="24717" xml_f="24992" txt_i="16348" txt_f="16623">Many studies claim that OLP is more predominant in females as they are more prone to stress and hormonal imbalance. However, in our study, we observed an equal distribution between males and females and this might be due to the small sample size as compared to other studies.</offsets></p><p><offsets xml_i="24999" xml_f="25033" txt_i="16624" txt_f="16658">In the studies conducted by Munde </offsets><italic><offsets xml_i="25041" xml_f="25046" txt_i="16658" txt_f="16663">et al</offsets></italic><offsets xml_i="25055" xml_f="25088" txt_i="16663" txt_f="16696">., Tak and Chalkoo, and Chitturi </offsets><italic><offsets xml_i="25096" xml_f="25101" txt_i="16696" txt_f="16701">et al</offsets></italic><offsets xml_i="25110" xml_f="25303" txt_i="16701" txt_f="16894">., the most common symptomatic form of LP was the erosive form. However, in the present study, the atrophic form was found to be more prevalent which is similar to a study conducted by Keshari </offsets><italic><offsets xml_i="25311" xml_f="25316" txt_i="16894" txt_f="16899">et al</offsets></italic><offsets xml_i="25325" xml_f="25383" txt_i="16899" txt_f="16957">. This variation could be due to the smaller sample size.[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="25417" xml_f="25419" txt_i="16957" txt_f="16959">13</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="25460" xml_f="25462" txt_i="16959" txt_f="16961">15</offsets></xref><xref rid="ref18" ref-type="bibr"><offsets xml_i="25503" xml_f="25505" txt_i="16961" txt_f="16963">18</offsets></xref><offsets xml_i="25512" xml_f="25513" txt_i="16963" txt_f="16964">]</offsets></p><p><offsets xml_i="25520" xml_f="25695" txt_i="16965" txt_f="17140">The most common site where OLP was seen in our study was in the buccal mucosa, followed by gingiva. This is in accordance with the studies conducted by Tak and Chalkoo, Munde </offsets><italic><offsets xml_i="25703" xml_f="25708" txt_i="17140" txt_f="17145">et al</offsets></italic><offsets xml_i="25717" xml_f="25743" txt_i="17145" txt_f="17171">., and Mostafa and Ahmed.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="25777" xml_f="25779" txt_i="17171" txt_f="17173">14</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="25820" xml_f="25822" txt_i="17173" txt_f="17175">15</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="25863" xml_f="25865" txt_i="17175" txt_f="17177">19</offsets></xref><offsets xml_i="25872" xml_f="25873" txt_i="17177" txt_f="17178">]</offsets></p><p><offsets xml_i="25880" xml_f="25915" txt_i="17179" txt_f="17214">The study conducted by Chainani-Wu </offsets><italic><offsets xml_i="25923" xml_f="25928" txt_i="17214" txt_f="17219">et al</offsets></italic><offsets xml_i="25937" xml_f="26102" txt_i="17219" txt_f="17384">. has reported that more than one mucosal surface can be involved which is in accordance with our study wherein a combination of gingiva and buccal mucosa was seen.[</offsets><xref rid="ref23" ref-type="bibr"><offsets xml_i="26136" xml_f="26138" txt_i="17384" txt_f="17386">23</offsets></xref><offsets xml_i="26145" xml_f="26146" txt_i="17386" txt_f="17387">]</offsets></p><p><offsets xml_i="26153" xml_f="26699" txt_i="17388" txt_f="17934">In the present study, the patients in both the groups, i.e., the study group and the control group reported a complete reduction in the intensity of pain at the second follow-up visit. An overall statistically significant improvement in the pain scores was found from baseline to second follow-up visit in both the groups, but no significant differences were observed between the two groups. In other words, an intragroup analysis showed significant differences in each group, but the intergroup analysis did not show any significant differences.</offsets></p><p><offsets xml_i="26706" xml_f="26977" txt_i="17935" txt_f="18206">In the control group, all the patients reported complete resolution of erythema at the second follow-up visit. An overall statistically significant improvement was found in the erythema scores in the control group patients from baseline to second follow-up visit [Figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="27007" xml_f="27009" txt_i="18206" txt_f="18208">2a</offsets></xref><offsets xml_i="27016" xml_f="27017" txt_i="18208" txt_f="18209">–</offsets><xref ref-type="fig" rid="F4"><offsets xml_i="27047" xml_f="27048" txt_i="18209" txt_f="18210">c</offsets></xref><offsets xml_i="27055" xml_f="27057" txt_i="18210" txt_f="18212">].</offsets></p><fig id="F4" position="float"><label><offsets xml_i="27098" xml_f="27106" txt_i="18213" txt_f="18221">Figure 2</offsets></label><caption><p><offsets xml_i="27126" xml_f="27646" txt_i="18221" txt_f="18741">(a) Patient with atrophic lichen planus at baseline visit included in the study group. (b) Reduction in severity of erythema following treatment with propolis at first follow-up visit. (c) Further reduction in erythema at the second follow-up visit. (d) Patient with atrophic lichen planus at baseline visit included in the control group. (e) Reduction in severity of erythema following treatment with triamcinolone acetonide 0.1% at first follow-up visit. (f) Further reduction in erythema at the second follow-up visit</offsets></p></caption><graphic xlink:href="CCD-9-65-g009"></graphic></fig><p><offsets xml_i="27715" xml_f="28028" txt_i="18742" txt_f="19055">Among 12 patients in the study group, 11 patients reported complete resolution of erythema and 1 patient had a score of 1 (mild erythema). There was an overall improvement in the erythema scores which was statistically significant. However, no significant differences were observed between the two groups [Figure </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="28058" xml_f="28060" txt_i="19055" txt_f="19057">2d</offsets></xref><offsets xml_i="28067" xml_f="28068" txt_i="19057" txt_f="19058">–</offsets><xref ref-type="fig" rid="F4"><offsets xml_i="28098" xml_f="28099" txt_i="19058" txt_f="19059">f</offsets></xref><offsets xml_i="28106" xml_f="28108" txt_i="19059" txt_f="19061">].</offsets></p><p><offsets xml_i="28115" xml_f="28185" txt_i="19062" txt_f="19132">The result of our study is comparable to the study conducted by Zydaa </offsets><italic><offsets xml_i="28193" xml_f="28198" txt_i="19132" txt_f="19137">et al</offsets></italic><offsets xml_i="28207" xml_f="28428" txt_i="19137" txt_f="19358">. to evaluate the efficacy of propolis in the management of LP. They also proved that propolis showed to be a promising pharmacological agent for inhibiting epithelial cell proliferation and has anti-inflammatory effect.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="28462" xml_f="28464" txt_i="19358" txt_f="19360">12</offsets></xref><offsets xml_i="28471" xml_f="28472" txt_i="19360" txt_f="19361">]</offsets></p><p><offsets xml_i="28479" xml_f="28916" txt_i="19362" txt_f="19799">According to our study, propolis is comparative in its efficacy to corticosteroids. It must be enunciated that topical propolis does not accord any adverse effects, unlike topical corticosteroids. Chiefly, the fatalistic effects demonstrated in topical steroid use such as oral candidiasis, mucosal atrophy, telangiectasia, hypersensitivity reactions, hypopigmentation, and delayed wound healing were eliminated in topical propolis use.[</offsets><xref rid="ref24" ref-type="bibr"><offsets xml_i="28950" xml_f="28952" txt_i="19799" txt_f="19801">24</offsets></xref><offsets xml_i="28959" xml_f="28960" txt_i="19801" txt_f="19802">]</offsets></p><p><offsets xml_i="28967" xml_f="29310" txt_i="19803" txt_f="20146">To the best of our knowledge, this is the first clinical trial to be conducted using propolis obtained from South Asia as a topical preparation in the management of OLP. Considering its safety, wide availability, and low cost, propolis could be a novel alternative therapeutic modality in the management of inflammatory conditions such as OLP.</offsets></p><sec id="sec2-6"><title><offsets xml_i="29338" xml_f="29375" txt_i="20147" txt_f="20184">Limitations and future recommendation</offsets></title><p><offsets xml_i="29386" xml_f="29742" txt_i="20185" txt_f="20541">A major limitation of this study was the small sample size. A larger sample size would have allowed for stronger statistical analysis. Another limitation of the study was the dependence on patient's compliance which could not be monitored. Furthermore, since the patients were followed up only till 14 days, the recurrence rate of LP could not be elicited.</offsets></p><p><offsets xml_i="29749" xml_f="29997" txt_i="20542" txt_f="20790">Future studies can be conducted using a larger sample size to further authenticate the effectiveness of propolis. A longer follow-up period will help in demonstrating a difference in the recurrence rate of LP among the study and the control groups.</offsets></p></sec></sec><sec sec-type="conclusion" id="sec1-5"><title><offsets xml_i="30059" xml_f="30069" txt_i="20793" txt_f="20803">Conclusion</offsets></title><p><offsets xml_i="30080" xml_f="30433" txt_i="20804" txt_f="21157">The current study comprised of 27 patients diagnosed with OLP, among which 15 patients were in the control group and the rest 12 were in the study group. The patients in the control group received triamcinolone acetonide 0.1% while the patients in the study group received 5% propolis. Both the groups were evaluated for pain and erythema at baseline (1</offsets><sup><offsets xml_i="30438" xml_f="30440" txt_i="21157" txt_f="21159">st</offsets></sup><offsets xml_i="30446" xml_f="30473" txt_i="21159" txt_f="21186"> visit), first follow-up (7</offsets><sup><offsets xml_i="30478" xml_f="30480" txt_i="21186" txt_f="21188">th</offsets></sup><offsets xml_i="30486" xml_f="30517" txt_i="21188" txt_f="21219"> day), and second follow-up (14</offsets><sup><offsets xml_i="30522" xml_f="30524" txt_i="21219" txt_f="21221">th</offsets></sup><offsets xml_i="30530" xml_f="30536" txt_i="21221" txt_f="21227"> day).</offsets></p><p><offsets xml_i="30543" xml_f="30803" txt_i="21228" txt_f="21488">The following conclusions were drawn: the topical propolis was found to be as effective as triamcinolone acetonide 0.1% in the management of OLP. It has both antioxidant and anti-inflammatory effects, which may significantly contribute to its clinical effects.</offsets></p><p><offsets xml_i="30810" xml_f="30956" txt_i="21489" txt_f="21635">No adverse reactions were noted with the use of topical propolis, and it was also found to be effective at the prescribed dose, i.e., 5% propolis.</offsets></p><p><offsets xml_i="30963" xml_f="31122" txt_i="21636" txt_f="21795">Considering the chronicity of the disease and the need for the long-term treatment modalities, propolis can be proposed as a better treatment modality for OLP.</offsets></p><p><offsets xml_i="31129" xml_f="31491" txt_i="21796" txt_f="22158">Considering the safety, wide availability, and low cost, propolis should be considered as a novel alternative therapeutic modality in the management of OLP. Hence, we conclude that our results provided practical hints for the better management of OLP. However, more research with larger sample size is necessary for a full evaluation of the efficacy of propolis.</offsets></p><sec id="sec2-7"><title><offsets xml_i="31519" xml_f="31552" txt_i="22159" txt_f="22192">Financial support and sponsorship</offsets></title><p><offsets xml_i="31563" xml_f="31567" txt_i="22193" txt_f="22197">Nil.</offsets></p></sec><sec id="sec2-8" sec-type="COI-statement"><title><offsets xml_i="31626" xml_f="31647" txt_i="22199" txt_f="22220">Conflicts of interest</offsets></title><p><offsets xml_i="31658" xml_f="31693" txt_i="22221" txt_f="22256">There are no conflicts of interest.</offsets></p></sec></sec></body><back><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehrotra</surname><given-names>V</given-names></name><name><surname>Devi</surname><given-names>P</given-names></name><name><surname>Bhovi</surname><given-names>TV</given-names></name><name><surname>Jyoti</surname><given-names>B</given-names></name></person-group><article-title>Mouth as a mirror of systemic diseases</article-title><source>Gomal J Med Sci</source><year>2010</year><volume>8</volume><fpage>235</fpage><lpage>41</lpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudhia</surname><given-names>BB</given-names></name><name><surname>Dudhia</surname><given-names>SB</given-names></name><name><surname>Patel</surname><given-names>PS</given-names></name><name><surname>Jani</surname><given-names>YV</given-names></name></person-group><article-title>Oral lichen planus to oral lichenoid lesions: Evolution or revolution</article-title><source>J Oral Maxillofac Pathol</source><year>2015</year><volume>19</volume><fpage>364</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">26980966</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Burket</surname><given-names>L</given-names></name><name><surname>Greenberg</surname><given-names>M</given-names></name><name><surname>Glick</surname><given-names>M</given-names></name><name><surname>Ship</surname><given-names>J</given-names></name></person-group><article-title>Burket's Oral Medicine</article-title><year>2008</year><publisher-loc>Hamilton, Ont</publisher-loc><publisher-name>BC Decker</publisher-name></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagh</surname><given-names>VD</given-names></name></person-group><article-title>Propolis: A wonder bees product and its pharmacological potentials</article-title><source>Adv Pharmacol Sci</source><year>2013</year><volume>2013</volume><fpage>308249</fpage><pub-id pub-id-type="pmid">24382957</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuropatnicki</surname><given-names>AK</given-names></name><name><surname>Szliszka</surname><given-names>E</given-names></name><name><surname>Krol</surname><given-names>W</given-names></name></person-group><article-title>Historical aspects of propolis research in modern times</article-title><source>Evid Based Complement Alternat Med</source><year>2013</year><volume>2013</volume><fpage>964149</fpage><pub-id pub-id-type="pmid">23710243</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arshiya Ara</surname><given-names>S</given-names></name><name><surname>Ashraf</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>V</given-names></name><name><surname>Rampure</surname><given-names>P</given-names></name></person-group><article-title>Use of apitherapy as a novel practice in the management of oral diseases: A review of literature</article-title><source>J Contemp Dent</source><year>2013</year><volume>3</volume><fpage>25</fpage><lpage>31</lpage></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Meij</surname><given-names>EH</given-names></name><name><surname>van der Waal</surname><given-names>I</given-names></name></person-group><article-title>Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications</article-title><source>J Oral Pathol Med</source><year>2003</year><volume>32</volume><fpage>507</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">12969224</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chainani-Wu</surname><given-names>N</given-names></name><name><surname>Silverman</surname><given-names>S</given-names><suffix>Jr</suffix></name><name><surname>Reingold</surname><given-names>A</given-names></name><name><surname>Bostrom</surname><given-names>A</given-names></name><name><surname>Lozada-Nur</surname><given-names>F</given-names></name><name><surname>Weintraub</surname><given-names>J</given-names></name></person-group><article-title>Validation of instruments to measure the symptoms and signs of oral lichen planus</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source><year>2008</year><volume>105</volume><fpage>51</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18155609</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>RR</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><name><surname>Batra</surname><given-names>M</given-names></name></person-group><article-title>Propolis in oral health: A natural remedy</article-title><source>World J Pharm Sci</source><year>2014</year><volume>2</volume><fpage>90</fpage><lpage>4</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouralibaba</surname><given-names>F</given-names></name><name><surname>Babaloo</surname><given-names>Z</given-names></name><name><surname>Pakdel</surname><given-names>F</given-names></name><name><surname>Aghazadeh</surname><given-names>M</given-names></name></person-group><article-title>Serum level of interleukin 17 in patients with erosive and non erosive oral lichen planus</article-title><source>J Dent Res Dent Clin Dent Prospects</source><year>2013</year><volume>7</volume><fpage>91</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">23875087</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zyada</surname><given-names>MM</given-names></name><name><surname>El-Said Elewa</surname><given-names>M</given-names></name><name><surname>El-Meadawy</surname><given-names>S</given-names></name><name><surname>El-Sharkawy</surname><given-names>H</given-names></name></person-group><article-title>Effectiveness of topical mucoadhesive gel containing propolis in management of patients with atrophic and erosive oral lichen planus: Clinical and immunohistochemical study</article-title><source>Egypt Dent Assoc</source><year>2012</year><volume>58</volume><fpage>1</fpage><lpage>3</lpage></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zenouz</surname><given-names>TA</given-names></name><name><surname>Mehdipour</surname><given-names>M</given-names></name><name><surname>Abadi</surname><given-names>RT</given-names></name><name><surname>Shokri</surname><given-names>J</given-names></name><name><surname>Rajaee</surname><given-names>M</given-names></name><name><surname>Aghazadeh</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Effect of use of propolis on serum levels of il-17 and clinical symptoms and signs in patients with ulcerative oral lichen planus</article-title><source>Oral Surg Oral Med Oral Pathol Oral Radiol</source><year>2015</year><volume>119</volume><fpage>166</fpage><lpage>7</lpage></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chitturi</surname><given-names>RT</given-names></name><name><surname>Sindhuja</surname><given-names>P</given-names></name><name><surname>Parameswar</surname><given-names>RA</given-names></name><name><surname>Nirmal</surname><given-names>RM</given-names></name><name><surname>Reddy</surname><given-names>BV</given-names></name><name><surname>Dineshshankar</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Aclinical study on oral lichen planus with special emphasis on hyperpigmentation</article-title><source>J Pharm Bioallied Sci</source><year>2015</year><volume>7</volume><fpage>S495</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26538905</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostafa</surname><given-names>B</given-names></name><name><surname>Ahmed</surname><given-names>E</given-names></name></person-group><article-title>Prevalence of oral lichen planus among a sample of the Egyptian population</article-title><source>J Clin Exp Dent</source><year>2015</year><volume>7</volume><fpage>e7</fpage><lpage>e12</lpage><pub-id pub-id-type="pmid">25810846</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tak</surname><given-names>MM</given-names></name><name><surname>Chalkoo</surname><given-names>AH</given-names></name></person-group><article-title>Demographic, clinical profile of oral lichen planus and its possible correlation with thyroid disorders: A case-control study</article-title><source>Int J Sci Stud</source><year>2015</year><volume>3</volume><fpage>19</fpage><lpage>23</lpage></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gümrü</surname><given-names>B</given-names></name></person-group><article-title>A retrospective study of 370 patients with oral lichen planus in turkey</article-title><source>Med Oral Patol Oral Cir Bucal</source><year>2013</year><volume>18</volume><fpage>e427</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">23524413</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keshari</surname><given-names>D</given-names></name><name><surname>Patil</surname><given-names>K</given-names></name><name><surname>Mahima</surname><given-names>VG</given-names></name></person-group><article-title>Efficacy of topical curcumin in the management of oral lichen planus: A randomized controlled-trial</article-title><source>J Adv Clin Res Insights</source><year>2015</year><volume>2</volume><fpage>197</fpage><lpage>203</lpage></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munde</surname><given-names>AD</given-names></name><name><surname>Karle</surname><given-names>RR</given-names></name><name><surname>Wankhede</surname><given-names>PK</given-names></name><name><surname>Shaikh</surname><given-names>SS</given-names></name><name><surname>Kulkurni</surname><given-names>M</given-names></name></person-group><article-title>Demographic and clinical profile of oral lichen planus: A retrospective study</article-title><source>Contemp Clin Dent</source><year>2013</year><volume>4</volume><fpage>181</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">24015006</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingafou</surname><given-names>M</given-names></name><name><surname>Leao</surname><given-names>JC</given-names></name><name><surname>Porter</surname><given-names>SR</given-names></name><name><surname>Scully</surname><given-names>C</given-names></name></person-group><article-title>Oral lichen planus: A retrospective study of 690 British patients</article-title><source>Oral Dis</source><year>2006</year><volume>12</volume><fpage>463</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16910916</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandolfo</surname><given-names>S</given-names></name><name><surname>Richiardi</surname><given-names>L</given-names></name><name><surname>Carrozzo</surname><given-names>M</given-names></name><name><surname>Broccoletti</surname><given-names>R</given-names></name><name><surname>Carbone</surname><given-names>M</given-names></name><name><surname>Pagano</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: A follow-up study in an Italian population</article-title><source>Oral Oncol</source><year>2004</year><volume>40</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">14662419</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacy</surname><given-names>MF</given-names></name><name><surname>Reade</surname><given-names>PC</given-names></name><name><surname>Hay</surname><given-names>KD</given-names></name></person-group><article-title>Lichen planus: A theory of pathogenesis</article-title><source>Oral Surg Oral Med Oral Pathol</source><year>1983</year><volume>56</volume><fpage>521</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6580596</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anjum</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>J</given-names></name><name><surname>Kuduva</surname><given-names>S</given-names></name></person-group><article-title>A clinicohistopathologic study and probable mechanism of pigmentation in oral lichen planus</article-title><source>World J Dent</source><year>2012</year><volume>3</volume><fpage>330</fpage><lpage>4</lpage></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chainani-Wu</surname><given-names>N</given-names></name><name><surname>Silverman</surname><given-names>S</given-names><suffix>Jr</suffix></name><name><surname>Lozada-Nur</surname><given-names>F</given-names></name><name><surname>Mayer</surname><given-names>P</given-names></name><name><surname>Watson</surname><given-names>JJ</given-names></name></person-group><article-title>Oral lichen planus: Patient profile, disease progression and treatment responses</article-title><source>J Am Dent Assoc</source><year>2001</year><volume>132</volume><fpage>901</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11480643</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Pawar</surname><given-names>CP</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name></person-group><article-title>Topical corticosteroids: Applications in dentistry</article-title><source>Santosh Univ J Health Sci</source><year>2015</year><volume>1</volume><fpage>99</fpage><lpage>101</lpage></element-citation></ref></ref-list></back></article>